Forte Biosciences, Inc.
NASDAQ:FBRXBiotechnology
+$0.30 today
- Market cap
- $1.58B
- Beta
- 2.87
- P/E (TTM)
- -42.1
- EPS (TTM)
- -$0.43
Volume 0.00M
Average 0.30M
FBRX Property, Plant & Equipment (Net)
Physical long-term assets such as land, buildings, and machinery, net of accumulated depreciation.
Forte Biosciences, Inc.NASDAQ: FBRX
Property, Plant & Equipment (Net) · Q1 FY2026 · quarter ended Mar 2026
Property, plant & equipment (net) falls 12.0% from a year ago
Property, plant & equipment (net) stood at $110K at the end of Q1 FY2026, down 12.0% from a year earlier and down 14.7% from the prior quarter.
Context
- Property, plant & equipment (net) amounted to 0.2% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Property, plant & equipment (net) increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether property, plant & equipment (net) keeps falling in the next quarterly balance sheet after a -12.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Property, Plant & Equipment (Net) history
USD · from the balance sheet
- Latest · FY2025
- 129K USD
- Year-over-year change
- +67.5%
| Period | Period end | Property, Plant & Equipment (Net) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 129K | +67.5% |
| FY2024 | 2024-12-31 | 77K | -29.4% |
| FY2023 | 2023-12-31 | 109K | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Property, Plant & Equipment (Net) vs competitors
How FBRX compares with its peers on the latest reported figures
- Peers report in different currencies, so property, plant & equipment (net) is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -12.0% is the 4th highest of 9, against a peer median of -18.3%.
- Property, plant & equipment (net) amounts to 0.2% of total assets for FBRX, versus a peer median of 9.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $98.3M USD | -9.1% | -2.1% | 26.4% | |
| Mar 2026 | $95.34M USD | -11.7% | +14.3% | 33.5% | |
| Mar 2026 | $22.62M USD | -35.9% | -22.8% | 9.4% | |
| Mar 2026 | $20.09M USD | -17.6% | -11.1% | 12.9% | |
ELTXElicio Therapeutics, Inc. | Mar 2026 | $4.79M USD | -19.0% | -15.8% | 21.1% |
| Mar 2026 | CHF 4.71M CHF | +14.4% | -10.3% | 5.4% | |
| Mar 2026 | $986K USD | -46.4% | -30.0% | 2.0% | |
| Mar 2026 | $914K USD | -58.2% | -39.1% | 0.6% | |
| Mar 2026 | $110K USD | -12.0% | — | 0.2% | |
ACTUActuate Therapeutics Inc | Mar 2026 | $0 USD | — | — | 0.0% |
| Peer median (excluding FBRX) | — | -18.3% | -13.4% | 9.4% | |
Competitors are the stored peer set for FBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Forte Biosciences, Inc.
NASDAQ:FBRX
Intrinsic Alpha fair value
Locked
Current Price
$76.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.